4.8 Review

Stimulus-Responsive Drug Delivery Nanoplatforms for Osteoarthritis Therapy

Journal

SMALL
Volume 19, Issue 23, Pages -

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/smll.202206929

Keywords

drug delivery; nanomedicine; osteoarthritis

Ask authors/readers for more resources

Osteoarthritis (OA) is a common age-related degenerative disease that poses economic and societal burdens, especially with the increasing aging population. Stimulus-responsive nanoplatforms offer improved therapeutic strategies for OA, with potential benefits such as enhanced control, longer retention time, higher loading rates, and increased sensitivity. This review summarizes the advanced application of stimulus-responsive drug delivery nanoplatforms, categorized by endogenous and exogenous stimuli, and discusses the opportunities, restrictions, and limitations of these systems.
Osteoarthritis (OA) is one of the most prevalent age-related degenerative diseases. With an increasingly aging global population, greater numbers of OA patients are providing clear economic and societal burdens. Surgical and pharmacological treatments are the most common and conventional therapeutic strategies for OA, but often fall considerably short of desired or optimal outcomes. With the development of stimulus-responsive nanoplatforms has come the potential for improved therapeutic strategies for OA. Enhanced control, longer retention time, higher loading rates, and increased sensitivity are among the potential benefits. This review summarizes the advanced application of stimulus-responsive drug delivery nanoplatforms for OA, categorized by either those that depend on endogenous stimulus (reactive oxygen species, pH, enzyme, and temperature), or those that depend on exogenous stimulus (near-infrared ray, ultrasound, magnetic fields). The opportunities, restrictions, and limitations related to these various drug delivery systems, or their combinations, are discussed in areas such as multi-functionality, image guidance, and multi-stimulus response. The remaining constraints and potential solutions that are represented by the clinical application of stimulus-responsive drug delivery nanoplatforms are finally summarized.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available